Article Text

Examining the utility of extended laboratory panel testing in the emergency department for risk stratification of patients with COVID-19: a single-centre retrospective service evaluation
  1. Mark J Ponsford1,2,
  2. Ross J Burton1,
  3. Leitchan Smith3,
  4. Palwasha Y Khan4,5,
  5. Robert Andrews6,
  6. Simone Cuff1,6,
  7. Laura Tan7,
  8. Matthias Eberl1,6,
  9. Ian R Humphreys1,6,
  10. Farbod Babolhavaeji8,
  11. Andreas Artemiou9,
  12. Manish Pandey7,
  13. Stephen R A Jolles2,
  14. Jonathan Underwood1,10
  1. 1 Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK
  2. 2 Immunodeficiency Center for Wales, University Hospital of Wales, Cardiff, UK
  3. 3 Information & Technology Team, University Hospital of Wales, Cardiff, UK
  4. 4 Department of Sexual Health, Cardiff and Vale UHB, Cardiff, UK
  5. 5 Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, UK
  6. 6 Systems Immunity Research Institute, Cardiff University, Cardiff, UK
  7. 7 Adult Critical Care Directorate, Cardiff and Vale UHB, Cardiff, UK
  8. 8 Department of Emergency Medicine, Cardiff and Vale UHB, Cardiff, UK
  9. 9 School of Mathematics, Cardiff University, Cardiff, UK
  10. 10 Department of Infectious Diseases, Cardiff and Vale UHB, Cardiff, UK
  1. Correspondence to Dr Mark J Ponsford, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK; ponsfordm{at}


Background The role of specific blood tests to predict poor prognosis in patients admitted with infection from SARS-CoV-2 remains uncertain. During the first wave of the global pandemic, an extended laboratory testing panel was integrated into the local pathway to guide triage and healthcare resource utilisation for emergency admissions. We conducted a retrospective service evaluation to determine the utility of extended tests (D-dimer, ferritin, high-sensitivity troponin I, lactate dehydrogenase and procalcitonin) compared with the core panel (full blood count, urea and electrolytes, liver function tests and C reactive protein).

Methods Clinical outcomes for adult patients with laboratory-confirmed COVID-19 admitted between 17 March and 30 June 2020 were extracted, alongside costs estimates for individual tests. Prognostic performance was assessed using multivariable logistic regression analysis with 28-day mortality used as the primary endpoint and a composite of 28-day intensive care escalation or mortality for secondary analysis.

Results From 13 500 emergency attendances, we identified 391 unique adults admitted with COVID-19. Of these, 113 died (29%) and 151 (39%) reached the composite endpoint. ‘Core’ test variables adjusted for age, gender and index of deprivation had a prognostic area under the curve of 0.79 (95% CI 0.67 to 0.91) for mortality and 0.70 (95% CI 0.56 to 0.84) for the composite endpoint. Addition of ‘extended’ test components did not improve on this.

Conclusion Our findings suggest use of the extended laboratory testing panel to risk stratify community-acquired COVID-19 positive patients on admission adds limited prognostic value. We suggest laboratory requesting should be targeted to patients with specific clinical indications.

  • infections
  • biochemistry
  • haematology
  • inflammation
  • costs and cost analysis

Data availability statement

Data are available on reasonable request. Requests for data sharing will be reviewed by a clinical and information regulatory governance panel and considered on an individual basis.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


In December 2019, COVID-19 was reported in China, caused by SARS-CoV-2.1 In the first year since its emergence, SARS-CoV-2 has caused over 79 million infections and more than a 1.7 million deaths worldwide.2 The majority of patients with COVID-19 experience a mild influenza-like illness; however, approximately 15%–25% of those admitted to hospital develop pneumonia that may evolve into acute respiratory distress syndrome.3–6 Experience from the Italian region of Lombardy highlighted the potential of uncontrolled COVID-19 outbreaks to rapidly overwhelm local intensive care capacity and healthcare systems.5 In the UK, Wales has one of the lowest number of intensive care beds per head of population in Europe,7 8 prompting implementation of scoring systems to support patient triage and allocation of healthcare resources.

The ability to identify patients at greatest risk of developing life-threatening complications from SARS-CoV-2 infection based on haematological and biochemical laboratory markers was suggested early in the pandemic. A range of admission tests including D-dimer, ferritin, high-sensitivity troponin I (hs-Trop) and lactate dehydrogenase (LDH) have been linked with disease severity and risk of death.9–13 Similar findings have been replicated in meta-analysis.14 Furthermore, use of a broader range of laboratory tests in patients with COVID-19 has been supported by the UK Royal College of Pathologists15 and the International Federation of Clinical Chemistry (IFCC).16 Accordingly, an extended panel of laboratory tests was integrated within the standard of care pathway for COVID-19 admissions presenting via the emergency eepartment (ED) of the University Hospital of Wales. This panel consisted of both ‘core’ (full blood count (FBC), urea and electrolytes (U&E), liver function tests (LFTs) and C reactive protein (CRP)) and ‘extended’ test components (D-dimer, LDH, ferritin, hs-Trop and procalcitonin (PCT)).

A joint National Health Service (NHS)–University collaboration supporting the rapid creation of an electronic healthcare registry (see online supplementary: extended methods) provided a timely opportunity to retrospectively assess the value and cost of implementing this extended laboratory panel. This is particularly relevant given a recent systematic review of methodological and reporting standards highlighting caution before extrapolating models and decision thresholds derived from prognostic biomarker studies into local clinical practice.17 The role of extended components remains poorly represented in prognostic studies within the UK population to date.4 17–20 We therefore conducted a service evaluation focusing on the ability of these tests to predict mortality or escalation to intensive care in the first 28 days following admission, in adult patients with PCR-confirmed COVID-19. Given extensive work in the existing literature concerning prognostic model development,21 we did not seek to develop an novel tool. Instead, our primary aim was to evaluate the additional value extended laboratory tests conferred to patient risk stratification when used in patients meeting nationally defined clinical admission criteria, relative to routine core tests. Our secondary aim was to explore the additional cost of extended testing components. Together, we reveal limited prognostic value associated with use of extended laboratory tests, directing refinement of a risk stratification panel with potential cost savings ahead of future waves of COVID-19.


Study population

We identified patients aged ≥18 years admitted between 17 March 2020 and 30 June 2020 via the ED of the University Hospital of Wales (Cardiff, UK). This 1000-bed hospital is a tertiary referral centre within the region with the greatest recorded total of COVID-19 case positives in Wales.22 Only patients with SARS-CoV-2 infection confirmed by PCR on nasopharyngeal swab and likely community-acquired disease (defined as swab positive between 14 days prior or 7 days following the date of initial emergency attendance) were included. The criteria for admission were defined by the All-Wales COVID-19 Pathway for Secondary Care Management Guideline (available:, with hypoxia (peripheral oxygen saturations <94% on room air) the primary triage criteria for admission. Patients transferred in from other hospitals were excluded. The primary dataset was extracted as part of a service evaluation to assist local care planning. A fully anonymised dataset was created by a member of the Health Board NHS IT team. Prior to anonymisation, the postcode was used to extract the Welsh Index of Multiple Deprivation (WIMD) for each patient, as obtained from As such, ethical approval was not required for this study.

Data fields including admission date, clinical outcomes and laboratory measurements were integrated into an electronic healthcare registry ‘Cardiff Hospital Records Database - CHoRD’ using a bespoke software package: CHoRDBuilder (see online supplemental file 1: extended methods). Laboratory test results from the index presentation reported within the first 72 hours of ED presentation were considered as candidate variables.

Supplemental material


Twenty-eight-day mortality was chosen as the primary endpoint in accordance with UK COVID-19 mortality reporting. To support generalisability between studies,4 18 we performed secondary analysis using the composite endpoint of 28-day mortality or admission to intensive care.

Laboratory testing panel

All testing was performed in the United Kingdom Accreditation Service-accredited Biochemistry, Immunology, and Haematology Laboratories at the University Hospital of Wales. Cost estimates were obtained from the Health Board Laboratory Medicine Directorate, reflecting consumables, reagent, analyser running and maintenance costs, and staff time chargeable to NHS test requestors.

Statistical analysis

Statistical significance testing was performed according to the data encountered: for categorical data, such as gender, Fisher’s exact or χ2 testing was performed. For continuous data, Welch’s t-tests were used if the assumptions of normality were met; otherwise, non-parametric Mann-Whitney U tests were employed. In edge cases, permutation testing was performed. Two-sided statistical significance was set at p<0.05, with Bonferroni correction for multiple testing.

Model development

Candidate laboratory variables were triaged for inclusion based on their membership of core or extended laboratory test panels, before a data-driven approach was applied. This included assessment of variability, individual p values corrected for multiple comparisons and multicollinearity with generation of a Spearman’s rank correlation matrix.

Logistic regression, support vector machines, random forest and gradient boosted trees were all considered for multivariate predictive models. Models with complexity greater than logistic regression were found to offer little improvement (data not shown). Multivariate logistic regression was implemented in Python (V.3.7) using the Scikit-Learn package (V.0.23)23 and Statsmodels (V.0.11). Complete case analysis was conducted to enable meaningful comparison between core and extended tests.

To minimise bias, models were evaluated using cross-validation with fivefolds, with stratification to account for class imbalance. Performance statistics are reported as the average across all folds with binomial proportion 95% CIs. Model discrimination was assessed by area under receiver operating characteristic curve (ROC AUC), accuracy (balanced by support) and weighted F1 score (the average F1 score was calculated for each class and weighted by support). In addition to these performance metrics, threshold-performance curves were generated to assess the effect of the decision threshold on model sensitivity and specificity.24 Source code for all models can be found on GitHub:

Our evaluation is reported using the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) guidance for Prediction Model development and validation (see online supplemental file 1).

Patient involvement

These data were generated as part of a rapid service improvement and as such patients were not involved in the setting of the research question or interpretation of the study.


Definition and overview of service evaluation cohort

We focused on admissions occurring after the operational roll-out of the first extended laboratory test panel components into standard clinical practice. During this 105-day period, over 13 500 ED attendances were recorded. Of these, 391 adults were admitted via ED with a laboratory-confirmed diagnosis of COVID-19 meeting our definition of likely community-acquired COVID-19 (figure 1). The median age was 69 years (IQR: 55–75 years) with males predominant (52.4%). Within 28 days of index ED attendance, 113 deaths occurred (29% mortality), and 151 patients reached the composite secondary endpoint of intensive care admission/death (39%).

Univariate analysis of laboratory predictors of adverse inpatient course

We next analysed the association between individual candidate variables and patient outcomes to identify important predictors of adverse outcome. Admission clinical variables are presented in table 1 (for full dataset, online supplemental files S1, S2). Advanced age was strongly associated with increased risk of death and the composite of ICU admission and death. In contrast, neither gender nor socioeconomic deprivation were associated with 28-day mortality. For laboratory variables, missing data were rare for core test panel components. Within the extended testing panel, hs-Trop and D-dimer were available in 70%–80% of patients admitted with COVID-19 within the first 72 hours of ED attendance. An early admission PCT test result was available in 40% of patients, while ferritin and LDH levels were recorded in 42%–46% of cases. Testing rates were similar between patient survival groups.

Table 1

Demographic and selected clinical laboratory predictor variables on admission for evaluation cohort

In univariate analysis of the core laboratory panel components, increased CRP, neutrophil:lymphocyte ratio, urea, creatinine or decrease in serum albumin were all strongly associated with risk of death. Within the extended panel, D-dimer, hs-Trop and PCT differed between survivors and non-survivors on univariate analysis (figure 2; online supplemental file S3). No extended panel members were associated with development of the composite outcome (online supplemental files S4, S5). Age was associated with several variables (online supplemental file S6), indicating it could confound the relationship between a test result and mortality.

Figure 2

Laboratory test results according to survival outcome and grouped by gender. Box and swarm plots showing the initial laboratory test results from laboratory-confirmed patients with COVID-19, grouped by gender and 28-day mortality. Example variables considered from the components of the core laboratory test panel. *Indicates level of significance, assessed by Mann-Whitney U test with correction for multiple testing: *P<0.05, **p<0.01, ***p<0.005, ****p<0.001.

Development of prognostic model based on core and extended laboratory admission test panels

We therefore used multivariate logistic regression to adjust for the role of age, while controlling for gender and WIMD, based on consistent identification of their contribution to outcomes in COVID-19 cohorts.21 25 Restricting to cases with complete data (n=130) across core and extended laboratory tests, we found an optimal combination of core test variables to be CRP, albumin, urea, neutrophil:lymphocyte ratio, creatinine, age, gender and WIMD (figure 3, online supplemental file S7). This gave a prognostic AUC of 0.79 (95% CI 0.67 to 0.91) for 28-day mortality and 0.70 (95% CI 0.56 to 0.84) for the composite outcome.

Figure 3

Prognostic performance of core and extended laboratory markers. Balanced accuracy (A), weighted F1 score (B), AUC score (C) and ROC curves (D) for models with sequential inclusion of extended biomarkers for prediction of 28-day mortality. AUC, area under the curve; LDH, lactate dehydrogenase; PCT, procalcitonin; ROC, receiver operating characteristic.

We next assessed the discriminative value associated with inclusion of extended panel components within our multivariate model, relative to this core test set (figure 3). Addition of D-dimer resulted in a marginal increase in mean AUC score to 0.82, but this was not significantly different (95% CI 0.71 to 0.85) to the performance of core testing alone. Concerning the composite outcome, addition of admission hs-Trop to the core panel resulted in the greatest AUC score: 0.72 (95% CI 0.60 to 0.83), but again, this did not represent a significant increase in performance to the core panel alone (online supplemental file S8). Consideration of extended test components individually or in combination did not improve on this. To internally validate these findings, we performed stratified cross-validation, observing convergence of training and validation curves, thus suggesting a low-risk of overfitting associated with these models (online supplemental file S9, S10). Assessing the calibration of these models across a range of performance metrics by varying the decision threshold (the probability at which a patient is predicted to either die or be admitted to intensive care), we found no significant benefit from addition of the extended relative to the core laboratory testing panel online supplemental file S11, S12). Adjusted ORs for the individual contribution of each variable to the prediction of 28-day mortality and composite outcome are presented in online supplemental file S13. For both outcomes, the additional variables included in the extended panel provide little influence over the predicted outcome.

Patterns of extended panel requesting during the first wave

Local cost estimates for NHS requesting the core laboratory panel totalled £16.44 per patient, with an additional £55.48 incurred for the extended set (online supplemental file S14). In order to contextualise testing beyond the cohort of community-acquired COVID-19, we constructed a run chart of test requesting within the first 72 hours of admission via ED and COVID-19 related admissions (figure 4). D-dimer and hs-Trop testing rates rose in line with COVID-19 admissions during March and April, with a 1–2 week delay apparent for LDH, ferritin and PCT requesting. Strikingly, while COVID-19 admissions declined following the April peak, the intensity of extended biomarker panel requesting remained. Using January and June 2020 to represent requesting patterns before and after the first wave of COVID-19, mean monthly requesting increased by 29.7%, 224% and 588% for hs-Trop, ferritin and LDH, respectively. In contrast, recorded monthly ED attendance fell by 24.0% over this period. PCT and quantitative D-dimer were specifically introduced in response to the pandemic but still averaged >50 daily test requests within the early admission period during June. Across the evaluation period, over 6400 D-dimer and 5400 PCT requests were made, with an estimated service cost of £246 000.

Figure 4

Daily COVID-19 admission rates and test requesting patterns during the early admission period. Run chart showing emergency unit (EU) admission rates for patients with confirmed laboratory-confirmed COVID-19 (right y-axis, dashed-line) and accompanying tests performed within 72 hours of emergency department attendance (left y-axis, solid-line) during the first wave of the COVID-19 pandemic. The dotted line indicates the roll-out of extended panel testing from 17 March 2020.


To support the effective and efficient use of resources through evidence-based clinical practice, we conducted a service evaluation determining the prognostic value associated with routinely performed laboratory investigation in 130 adults admitted with community acquired SARS-CoV-2 infection. By leveraging a bespoke electronic healthcare registry, we reveal an extended panel (including D-dimer, LDH, hs-Trop, ferritin and PCT) provided only limited additional prognostic information beyond that provided by components of the core panel (FBC, U&E, LFT and and CRP). Together, this directs refinement of the clinical testing panel employed before and during future potential waves, underlining the relevance of this registry approach to support cost-utility of investigation pathways.

We identified five studies within the peer-reviewed and preprint literature concerning laboratory biomarker risk stratification of adult COVID-19 admissions in the UK population.4 17–20 The largest reported, an 8-point pragmatic risk score developed by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC), achieved a modest AUC performance score of 0.77 (95% CI 0.76 to 0.77) when predicting 28-day mortality.19 To date, only one UK study has considered the prognostic role of variables within our extended laboratory panel.18 In their prospective analysis of 155 patients, Arnold et al 18 found conventional laboratory biomarkers such as CRP and neutrophil elevation offered limited prognostic performance (with AUC scores of 0.52 and 0.54, respectively), while ferritin, PCT, hs-Trop and LDH performed with AUC scores of 0.65 to 0.71. It is important to note that within this study cohort, the incidence of clinical deterioration was low (overall mortality was only 4% vs 29% for our service evaluation), which may have limited the power of the study. This highlights regional variation in rates of hospitalisation and mortality and further motivated a locally led assessment of practice.

Consistent with the emerging COVID-19 literature, we observed an association between laboratory markers of acute phase inflammatory response (elevated neutrophil count, CRP, depressed lymphocytes and albumin), cardiac injury, activation of thrombosis and renal impairment with subsequent adverse outcome.6 21 26 We found a combination of CRP, albumin, urea, neutrophil:lymphocyte ratio and creatinine alongside simple demographics achieved an AUC of 0.79 (95% CI 0.67 to 0.91) when predicting 28-day mortality and 0.70 (95% CI 0.56 to 0.84) for the composite endpoint. Importantly, we found no evidence that use of this panel at admission significantly improved performance for either outcome, consistent with international reports revealing limited value of admission and serial D-dimer testing with regard to prognostic yield.27 Addition of the extended laboratory test panel equates to £54 per patient (a relative cost increase of over 400% to the core panel alone), with significant cost ramifications when performed at scale. At a local level, we also identified use of the extended laboratory panel continued despite falling rates of COVID-19 presentations, allowing feedback to requesting teams and directly changing practice.

Our service evaluation has several strengths, notably assessment of the performance of an extended panel of laboratory tests not widely considered in UK prognostic studies to date within a clinical cohort identified based on commonly used clinical and virological criteria.4 17–20 Laboratory tests were integrated into routine practice prior to the local peak of the pandemic based on available literature and national guidelines.15 In contrast with the batched analysis undertaken under research condition in previous studies,18 all tests described here were conducted by accredited laboratories using platforms calibrated to international reference standards, facilitating future data sharing. Our multivariate approach is well suited to investigate whether specific laboratory tests provide additional prognostic value beyond conventional parameters,28 using inclusion criteria and clinically relevant endpoints in line with other reported studies.4 17 19 Finally, we considered the service costs that accompanied implementing these tests into routine practice,29 a relevant factor often neglected in other publications.

Our evaluation also has a number of limitations, reflecting the challenges of clinical data collection during an epidemic. It represents retrospective experience from a single tertiary referral centre, limiting sample size. However, the study cohort inclusion criteria reflected national admission criteria for COVID-19 that remain active as the UK enters the next wave of COVID-19, highlighting the likely wider relevance of these findings. Second, availability of extended test panel results during the early admission period was mixed. Admission D-dimer and hs-Trop results were available for 70%–80% of patients, comparing favourably to a similar UK registry-based study where D-dimer results were only available at time of admission in 37.2%.17 Conversely, we observed high rates of missing data for LDH, ferritin and PCT, undermining their relevance as a prognostic tool. This was likely due to operational factors such as a delay in test roll out relative to epidemic peak, and requirement for an additional sample tube. Because it cannot be assumed that data are missing at random, we chose to perform complete case analysis. Although this limits our statistical power, it avoids unfounded assumptions and potentially invalid imputation. In its current form, the CHoRD registry lacks detailed information on patient-level physiological observations, nature of comorbidities, cause of death and therapeutic interventions. Similarly, all registry-linked laboratory values were available to clinicians and are likely to have influenced management decisions. Advances in clinical care diagnostics, therapeutics and potentially viral mutation are likely to alter the observed performance of the prognostic model. These limitations apply equally to pragmatic risk-scores,4 18 19 and the utility of risk stratification tools may vary over time.30 Finally, we recognise our evaluation consider the index test result and a specific question of inpatient prognosis, and additional indications exist for requesting components of the extended laboratory tests that fall outside of our primary and secondary endpoints. For instance, the use of PCT is often employed to support antibiotic stewardship31 and was integrated into routine practice locally in early April 2020. There may also be merit in more targeted use of additional testing. For example, a combination of routine and extended laboratory blood tests have recently been shown to support prediction of SARS-CoV-2 infection32; however, the cost-efficacy relative implementation of serial universal PCR screening remains uncertain. Hence, while we highlight the significant associated healthcare costs with implementation of extended laboratory testing, we do not make specific claims concerning the potential savings from discontinuing unnecessary investigations.29

Implications for practice

Laboratory markers supporting early risk stratification of patients are often used in the ED setting and have been shown to benefit patient triage.33 Our data suggest that systematic testing of COVID-19 positive patients on admission with an ‘extended’ laboratory panel provide little additional prognostic information for COVID-19 mortality or intensive care admission ‘core’ tests. Besides the financial impact, over-requesting of laboratory tests are likely to increase the number of false-positive results, with the potential to lead to further potentially harmful tests (eg, CT pulmonary angiography in patients with marginally elevated D-dimer but no clinical indication of thromboembolic disease).34 We suggest that the use of these laboratory markers be targeted to patients with specific clinical indications for these, such as PCT to guide antibiotic prescription or hs-Trop in patients with suspected myocardial injury.

In conclusion, we report our real-world experience from the use of an extended laboratory prognostic testing panel in patients hospitalised with community-acquired COVID-19. These findings directly inform clinical practice, guiding cost-efficient use of resources in potential future waves.

Take home messages

  • During the first wave of the pandemic, the literature and guidance from the UK Royal College of Pathologists supported the use of extended biochemistry and haematology testing on admission to support risk stratification of patients with COVID-19 infection; however, the prognostic performance of these markers remains unclear.

  • Our service evaluation suggests that systematic testing of COVID-19 positive patients with likely community-acquired disease on admission with an ‘extended’ laboratory panel (high-sensitivity troponin I, ferritin, lactate dehydrogenase, procalcitonin or quantitative D-dimer) provides limited additional prognostic information for 28-day mortality or intensive care admission, relative to conventional ‘core’ tests such as a full blood count, renal function and C reactive protein combined with simple demographics.

  • Few clinicians know the cost of the tests they request for their patients. With individual ‘extended’ panel members costing over £20 per test, and thousands of tests requested per month within a single hospital, these costs quickly escalate.

  • Besides the financial impact, over-requesting of laboratory tests are likely to increase the number of false-positive results, with the potential to lead to further potentially harmful investigations (eg, CT pulmonary angiography in patients with marginally elevated D-dimer but no clinical indication of thromboembolic disease). We suggest that the use of these laboratory markers be targeted to patients with specific clinical indications for these, such as procalcitonin to guide antibiotic stewardship or hs-Troponin I in patients with suspected myocardial injury.

Data availability statement

Data are available on reasonable request. Requests for data sharing will be reviewed by a clinical and information regulatory governance panel and considered on an individual basis.

Ethics statements

Patient consent for publication


We would like to thank James Webb and Philip Clee (National Health Service IT governance) for their advice and guidance in facilitating the Electronic Healthcare Registry underpinning this service evaluation, and Nigel Roberts and Alun Roderick for assistance in providing costings for laboratory tests. Additional support was provided by Professor Valentina Escott-Price, Dr Martyn Stones and Dr Irina Erchova.


Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.


  • Handling editor Tahir S Pillay.

  • Twitter @WCATImmunology, @burtondatasci, @dopapus, @eberlmat, @irhumphreys, @EmergencyBod, @Dr_J_Underwood

  • MJP and RJB contributed equally.

  • Contributors MJP and SRAJ conceived the service evaluation. MJP wrote the first draft, supervised by SRAJ and JU. LS, RA and RJB performed initial data extraction. RJB constructed Cardiff Hospital Admissions Database and led data analysis support for multivariate modelling from AA and PYK. All authors contributed scientific and clinical guidance regarding design and feature selection and have reviewed the final draft.

  • Funding This work was partly funded by UK Research and Innovation/ National Institute for Health Research (UKRI/NIHR) through the UK Coronavirus Immunology Consortium. MJP was supported by the Welsh Clinical Academic Training programme and a Career Development Award from the Association of Clinical Pathologists, and is a participant in the National Institutes of Health Graduate Partnership Programme. RJB was supported by a School of Medicine PhD Studentship (to RJB); IRH was supported by Wellcome Trust Senior Research Fellow; ME was supported by the Welsh European Funding Office’s Accelerate programme; JU was supported by Medical Research Council (MRC)-NIHR Clinical Academic Research Partnership (grant number MR/T023791/1).

  • Disclaimer The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.

  • Competing interests SRAJ has participated in advisory boards, trials and projects and has been a speaker CSL Behring, Takeda, Thermofisher, Swedish Orphan Biovitrum, Biotest, Binding Site, BPL, Octapharma, Sanofi, LFB, Pharming, Biocryst, Zarodex, Weatherden and UCB Pharma.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.